Skip to content
10-K

Annual Report

Pyxis Oncology, Inc. PYXS

0000950170-25-040771

← back to feed
Filed
Mar 18, 2025 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2024 · Mar 17, 2025 61.59M sh
Shares Diluted FY 2024 · Dec 31, 2023 39.9M sh
Capex FY 2024 · Dec 31, 2023 $6.73M
Operating Cash Flow FY 2024 · Dec 31, 2023 −$70.71M
Cash And Equivalents FY 2024 · Dec 31, 2023 $9.66M
Current Liabilities FY 2024 · Dec 31, 2023 $25.76M
Total Liabilities FY 2024 · Dec 31, 2023 $48.02M
Current Assets FY 2024 · Dec 31, 2023 $124.6M
Total Assets FY 2024 · Dec 31, 2023 $173.73M
Eps Diluted FY 2024 · Dec 31, 2023 −$1.85
Eps Basic FY 2024 · Dec 31, 2023 −$1.85
Sga Expense FY 2024 · Dec 31, 2023 $32.61M
Rd Expense FY 2024 · Dec 31, 2023 $49.59M
Net Income FY 2024 · Dec 31, 2023 −$73.79M
Operating Income FY 2024 · Dec 31, 2023 −$82.2M
Stockholders Equity FY 2024 · Dec 31, 2022 $160.82M